EGFR and non-small cell lung carcinoma: Based on previous studies [1–4], gefitinib or erlotinib, epidermal growth factor receptor mutation - tyrosine kinase inhibitor (EGFR-TKI), has been a successful regimen managing advanced non-small cell lung cancer (NSCLC).